Tempest Therapeutics, Inc
Price
FilingsNewest: 424B3, ProspectusOct 2 →Insiders1 insider bought $1.0M in 2 open-market buys. No sales.→HoldersSabby 3.2%Vanguard 1.5%Geode 0.5%→Financing →PeersClosest companies: PMVP, IMNM, TYRA→
From the filings
Figures
- Net income
- −$40.5Mlast 12 months
- Operating cash flow
- −$26.4Mlast 12 months
- Cash and equivalents
- $779,000at the last balance sheet
- Total debt
- $0.00at the last balance sheet
- Shares outstanding
- 16.0M shareson issue